NYU Langone Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).
NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.
NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,164 total, page 23 of 24
Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
NCT00201123
Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
NCT02280252
Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy
NCT02606708
Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma
NCT00531570
Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa
NCT00134134
Blood Pressure Control in African Americans
NCT00233220
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
NCT00444678
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
NCT00463840
NYU Ovarian Cancer Early Detection Program Blood and Genetics
NCT00531778
Surgical Debulking of Pituitary Adenomas
NCT01371643
A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions
NCT00104195
SAM-e for the Treatment of Depression in Patients With Parkinson's Disease
NCT00070941
Omega-3 Fatty Acids in Tourette's Disorder
NCT01315327
Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
NCT00858338
Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus
NCT00412841
Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)
NCT00285584
Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
NCT02297230
Disease Modifying Genes in Severe Asthma
NCT00212537
Treatment for Women With Post-Traumatic Stress Disorder Related to Childhood Abuse
NCT00069381
Cancer Screening and Prevention Program for High Risk Women
NCT00849199
Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI
NCT00245648
Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain
NCT00025311
Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
NCT00007358
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
NCT00025558
R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors
NCT00005990
Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00006391
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00010023
Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
NCT00418132
Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer
NCT00006825
Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer
NCT00010010
Safety Study of the Hypo-fractionated (Large Doses) Radiation Therapy in Post-menopausal Women With Breast Cancers
NCT02883985
Occluded Artery Trial (OAT)
NCT00004562
R115777 in Treating Patients With Relapsed Small Cell Lung Cancer
NCT00005041
Computed Tomography for Early Detection of Cancer in Women Who Are at Risk for Lung Cancer
NCT00012103
Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer
NCT00005050
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
NCT00005051
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00004002
Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme
NCT00010036
Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat
NCT00012168
Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
NCT00009997
Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer
NCT00004083
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
NCT00004102
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
NCT00004033
Combination Chemotherapy in Treating Patients With Advanced Cancer
NCT00004105
Chemotherapy in Treating Patients With Breast Cancer
NCT00012129
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
NCT00003548
Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer
NCT00004103
Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma
NCT00004104
Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer
NCT00003132
Combination Chemotherapy in Treating Patients With Advanced Cancer
NCT00003331
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 99 |
| Phase 2 | 132 |
| Phase 3 | 28 |
| Phase 4 | 95 |
Therapeutic Areas
What is open in the NYU Langone Health pipeline
197 recruiting of 1,164 indexed (17% open); 741 completed (64%).
Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NYU Langone Health: open-pipeline peers nationwide
Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,164 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this NYU Langone Health page
1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.
- 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.